【US Stock Market Movement】Grail plummeted on October 16th: unresolved approval, high valuation, and rapid correction after surge

Grail October 16 Major Drop Interpretation

Keywords: Pending approval, high valuation, rapid rise and correction

1. On September 23, 2026, the FDA advisory committee supported the safety and risk-benefit profile of Galleri, but the efficacy vote was 6 to 4, and the recommendation was non-binding. As of October 11, the final FDA approval was still pending, and the outlook for commercial insurance coverage remains uncertain.

2. As of October 7, 2026, GRAIL's share price had risen about 74% in one month, with a price-to-sales ratio of approximately 34 times. Comments on October 11 also pointed out that test pricing, follow-up examination costs, and insurance coverage are key commercial considerations. After an initial surge, valuation digestion may increase pressure for a share price correction.

(Disclaimer: This content is a summary generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)